Application and research progress of antibody drug conjugates in HER2 positive advanced gastric cancer
Gastric cancer is a malignant tumor with high heterogeneity and invasiveness. Its incidence rate ranks fifth in the world, and its mortality ranks third in the world. Most patients are in a state that cancer cannot be removed by surgery when symptoms appear. At present, systemic treatment is the mai...
Main Author: | KANG Yinnan, CHEN Shun, XIE Youcheng, ZHENG Ying, HE Yujing, LI Chuyi, YU Xiaohui |
---|---|
Format: | Article |
Language: | English |
Published: |
Editorial Office of China Oncology
2023-08-01
|
Series: | Zhongguo aizheng zazhi |
Subjects: | |
Online Access: | http://www.china-oncology.com/fileup/1007-3639/PDF/1693553443752-617911711.pdf |
Similar Items
-
Advances in the Application of Antibody Drug Conjugate in Gastric Cancer with Low Expression of Human Epidermal Growth Factor Receptor 2
by: KANG Yinnan, SHI Jiaqi, WANG Junke, LI Bin, LI Chuyi, MA Jun, YU Xiaohui
Published: (2024-06-01) -
Research Progress of Antibody–Drug Conjugate Therapy for Advanced Gastric Cancer
by: Na Wang, et al.
Published: (2022-05-01) -
Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer
by: Minghui Yu, et al.
Published: (2023-03-01) -
Antibody-drug conjugates: the clinical development in gastric cancer
by: Yingze Zhu, et al.
Published: (2023-05-01) -
Research Progress of Antibody-drug Conjugates in Small-cell Lung Cancer
by: HAN Jing, et al.
Published: (2023-11-01)